The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study

64Citations
Citations of this article
77Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Gastrointestinal stromal tumors (GIST) mutational status is recognized factor related to the results of tyrosine kinase inhibitors therapy such as imatinib (IM) or sunitinib (SU). Arterial hypertension (AH) is common adverse event related to SU, reported as predictive factor in renal cell carcinoma. The aim of the study was to analyze the outcomes and factors predicting results of SU therapy in inoperable/metastatic CD117(+) GIST patients after IM failure.Methods: We identified 137 consecutive patients with advanced inoperable/metastatic GIST treated in one center with SU (2 ndline treatment). Median follow-up time was 23 months. Additionally, in 39 patients there were analyzed selected constitutive single nucleotide polymorphisms (SNPs) of VEGFA and VEGFR2 genes.Results: One year progression-free survival (PFS; calculated from the start of SU) rate was 42% and median PFS was 43 weeks. The estimated overall survival (OS, calculated both from start of SU or IM) was 74 weeks and 51 months, respectively. One-year PFS was 65% (median 74 weeks) in 55 patients with AH vs. 22% (median 17 weeks) in patients without AH. Patients with primary tumors carrying mutations in KIT exon 9 or wild-type had substantially better 1-year PFS (68% and 57%; median 65.5 and 50.5 weeks, respectively) than patients having tumors with KIT exon 11 or PDGFRA mutations (34% and 15%; median 36.8 and 9 weeks, respectively). We identified two independent factors with significant impact on PFS and OS in univariate and multivariate analysis: primary tumor genotype and presence of AH. The most common adverse events during therapy were: fatigue, AH, hypothyroidism, hand and foot syndrome, mucositis, skin reactions, dyspepsia, and diarrhea. Two deaths were assessed as related to tumor rupture caused by reaction to SU therapy. The presence of C-allele in rs833061 and the T-allele in rs3025039 polymorphism of VEGFA were associated with significantly higher risk of hypothyroidism (OR: 10.0 p = 0.041 and OR: 10.5; p = 0.015, respectively).Conclusions: We confirmed that many advanced GIST patients benefit from SU therapy with OS > 1.5 year. Primary tumor KIT/PDGFRA genotype and SU-induced AH, as surrogate of its antiangiogenic activity are two independent factors influencing both PFS and OS.Note: The preliminary data of this study were presented during Annual Meeting of American Society of Clinical Oncology, 4-8 June 2011 and Connective Tissue Oncology Society Meeting, 26-28 October 2011 in Chicago, IL. © 2012 Rutkowski et al; licensee BioMed Central Ltd.

References Powered by Scopus

New guidelines to evaluate the response to treatment in solid tumors

14954Citations
N/AReaders
Get full text

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

3941Citations
N/AReaders
Get full text

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

2337Citations
N/AReaders
Get full text

Cited by Powered by Scopus

A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular Cancer

141Citations
N/AReaders
Get full text

Thyroid dysfunction as an unintended side effect of anticancer drugs

91Citations
N/AReaders
Get full text

Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension

82Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Rutkowski, P., Bylina, E., Klimczak, A., Świtaj, T., Falkowski, S., Kroc, J., … Limon, J. (2012). The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study. BMC Cancer, 12. https://doi.org/10.1186/1471-2407-12-107

Readers over time

‘12‘13‘14‘15‘16‘17‘18‘19‘20‘21‘22‘23‘24‘250481216

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 20

45%

Researcher 17

39%

Professor / Associate Prof. 5

11%

Lecturer / Post doc 2

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 26

55%

Biochemistry, Genetics and Molecular Bi... 10

21%

Agricultural and Biological Sciences 6

13%

Pharmacology, Toxicology and Pharmaceut... 5

11%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 1915

Save time finding and organizing research with Mendeley

Sign up for free
0